Clinical TrialMay 26, 2026, 08:11 AM
Genprex Reqorsa Biomarker Data Shows Prolonged PFS in NSCLC Patients
AI Summary
Genprex announced the publication of an abstract at the 2026 ASCO Annual Meeting, detailing positive clinical data for its lead drug candidate, Reqorsa® Gene Therapy. The studies identified predictive biomarkers, Trop-2 and PTEN, that correlate with prolonged Progression Free Survival in Non-Small Cell Lung Cancer patients receiving Reqorsa. This clinical validation supports earlier preclinical findings and suggests potential for targeted patient selection and precision medicine.
Key Highlights
- Genprex's research collaborators' abstract on Reqorsa biomarkers published at 2026 ASCO Annual Meeting.
- Positive clinical data details predictive biomarkers for Reqorsa® Gene Therapy in lung cancer patients.
- NSCLC patients with Trop-2 H-scores above 100 correlated with prolonged PFS (p=0.05).
- NSCLC patients with PTEN H-scores below 100 correlated with prolonged PFS (p=0.03).
- SCLC patients did not show correlation between Trop-2 or PTEN H-scores and prolonged PFS.
- Additional analysis showed 3+ Trop-2 staining in NSCLC had a strong relationship with PFS (p=0.053).
- Identified biomarkers may predict patient response and enable targeted patient selection for Reqorsa.
Price Impact
More from GNPX